Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting.
Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward.
Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer.
Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.
According to the researchers, these data suggest that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is very likely to succeed in a phase III trial.
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.
In this study, most clinical combinations including PD-1 or PD-L1 inhibitors demonstrated more clinical activity than the monotherapy activity of the checkpoint inhibitor alone.
The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them.
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.